Clinical trial
Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term…
NCT00439725 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00439725 |
|---|---|
| Title | Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study |
| Official title | Once-daily Oral Direct Factor Xa Inhibitor Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism. The Einstein-Extension Study |
| Lead sponsor | Bayer, Industry |
| Collaborators | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Venous Thromboembolism |
| Intervention type | Drug |
| Interventions | Rivaroxaban (Xarelto, BAY59-7939), Placebo |
| Enrollment | 1,197 |
| Start date | Feb 1, 2007 |
| Primary completion | Aug 1, 2009 |
| Completion | Sep 1, 2009 |
| First posted | Feb 26, 2007 |
| Last update posted | Nov 4, 2014 |
| Countries | Australia, Austria, Belgium, Brazil, Canada, China, Czechia, Denmark, Finland, France, Germany, Hong Kong and 21 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: